Abstract

French researchers have shown that their dendrimer against the receptor for M-CSF blocks inflammation, cartilage degradation and bone erosion in mouse models of rheumatoid arthritis. The team is getting the compound ready for clinical trials.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call